MUMBAI, India — Glenmark Pharmaceuticals Inc. USA has been granted final approval by the Food and Drug Administration for calcipotriene cream, a psoriasis medication.

Glenmark said Thursday that it plans to begin shipping of its calcipotriene cream product, a generic version of Dovonex Cream 0.005% from Leo Pharma A/S, immediately.

A form of vitamin D, calcipotriene topical is used for the treatment of plaque psoriasis.

The Dovonex market, including all branded products and therapeutic equivalents, had U.S. sales of $91.9 million for the 12 months ending in April, according to IMS Health data reported by Glenmark.